This database contains 350 studies, archived under the term: "therapeutic use"
Click here to filter this large number of results.
Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial
Sullivan, Mark D.,
Katon, Wayne J.,
Lovato, Laura C.,
Miller, Michael E.,
Murray, Anne M.,
Horowitz, Karen R.,
Bryan, R. Nick,
Gerstein, Hertzel C.,
Marcovina, Santica,
Akpunonu, Basil E.,
Johnson, Janice,
Yale, Jean Francois,
Williamson, Jeff,
Launer, Lenore J.
Importance: Depression has been identified as a risk factor for dementia among patients with type 2 diabetes mellitus but the cognitive domains and patient groups most affected have not been identified.; Objective: To determine whether comorbid depression in patients with type 2 diabetes accelerates cognitive decline.; Design: A 40-month cohort study of participants in the […]
Angiotensin-converting enzyme inhibitors and Alzheimer’s disease progression in older adults: results from the Réseau sur la Maladie d’Alzheimer Français cohort
Soto, Maria E.,
Abellan van Kan, Gabor,
Nourhashemi, Fati,
Gillette-Guyonnet, Sophie,
Cesari, Matteo,
Cantet, Christelle,
Rolland, Yves,
Vellas, Bruno
Objectives: To assess whether angiotensin-converting enzyme inhibitor (ACE-I) treatment is associated with less cognitive decline in older adults with Alzheimer’s disease (AD) than in those using other hypertensive or no drugs.; Design: Four-year prospective multicenter cohort study with a biannual assessment.; Setting: Memory clinics from 16 university hospitals in France.; Participants: Community-dwelling older adults with […]
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study
Sink, Kaycee M.,
Leng, Xiaoyan,
Williamson, Jeff,
Kritchevsky, Stephen B.,
Yaffe, Kristine,
Kuller, Lewis,
Yasar, Sevil,
Atkinson, Hal,
Robbins, Mike,
Psaty, Bruce,
Goff, David C.
Background: Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.; Methods: Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; […]
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study
Simioni, S.,
Cavassini, M.,
Annoni, J.-M.,
Metral, M.,
Iglesias, K.,
Rimbault Abraham, A.,
Jilek, S.,
Calmy, A.,
Muller, H.,
Fayet-Mello, A.,
Giacobini, E.,
Hirschel, B.,
Du Pasquier, R. A.
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.; Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by […]
A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease
Shinto, Lynne,
Quinn, Joseph,
Montine, Thomas,
Dodge, Hiroko H.,
Woodward, William,
Baldauf-Wagner, Sara,
Waichunas, Dana,
Bumgarner, Lauren,
Bourdette, Dennis,
Silbert, Lisa,
Kaye, Jeffrey
Oxidative stress, inflammation, and increased cholesterol levels are all mechanisms that have been associated with Alzheimer’s disease (AD) pathology. Several epidemiologic studies have reported a decreased risk of AD with fish consumption. This pilot study was designed to evaluate the effects of supplementation with omega-3 fatty acids alone (ω-3) or omega-3 plus alpha lipoic acid […]
A randomized controlled trial of estrogen treatment in men with mild cognitive impairment
This randomized, placebo-controlled, cross-over study investigated whether estrogen treatment would have a beneficial effect on tests of verbal memory in men with mild cognitive impairment (MCI). Forty-three men newly diagnosed with MCI were administered a battery of neuropsychological tests before randomly receiving 12 weeks of treatment with estrogen or placebo followed by a 12 week […]
Cognitive function in early clinical phase huntington disease after rivastigmine treatment
Background: In Huntington disease (HD) patients receiving rivastigmine treatment improvement of behavioral symptoms and of cognitive function (assessed with screening diagnostic instruments) has been reported. The aim of the present study was to verify such improvement in cognitive function by cognitive function assessment with a detailed neuropsychological battery covering all relevant cognitive systems expected to […]
A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease
Schwam, Elias M.,
Nicholas, Timothy,
Chew, Robert,
Billing, Clare B.,
Davidson, Wendy,
Ambrose, Darlene,
Altstiel, Larry D.
Background: PF-04447943 is a potent, selective phosphodiesterase 9A (PDE9A) inhibitor that elevates guanoscine 3′,5′ – cyclic monophosphate (cGMP) in brain and cerebrospinal fluid. PDE9A inhibition enhances synaptic plasticity and improves memory in preclinical cognition models, and prevents decreases in dendritic spine density in transgenic mice that overexpress amyloid precursor protein (APP) leading to high levels […]